Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Edgewise Therapeutics Inc (NQ: EWTX ) 36.62 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Edgewise Therapeutics Inc < Previous 1 2 3 4 5 6 Next > 10 Health Care Stocks With Whale Alerts In Today's Session October 16, 2024 Via Benzinga Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society October 01, 2024 From Edgewise Therapeutics Via Business Wire MarketBeat Week in Review – 9/23 - 9/27 September 28, 2024 Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally Via MarketBeat Topics Economy Exposures Economy Interest Rates Analysts Think There's Still Time to Get in on Edgewise, Up 332% September 25, 2024 Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? Via MarketBeat Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. Via Benzinga Topics Economy Exposures Interest Rates Crude Oil Gains Over 1%; Mobileye Global Shares Jump September 19, 2024 Via Benzinga Exposures Fossil Fuels Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge September 19, 2024 Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead. Via MarketBeat Why Edgewise Therapeutics Stock Is Up 50% on Thursday September 19, 2024 One of the biopharma company's heart drugs performs as well as initially hoped. Via The Motley Fool Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings September 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment September 19, 2024 Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT... Via Benzinga Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday September 19, 2024 Via Benzinga Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip September 19, 2024 Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. Via Investor's Business Daily Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) September 19, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time September 17, 2024 From Edgewise Therapeutics Via Business Wire EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024 August 08, 2024 EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 08, 2024 From Edgewise Therapeutics Via Business Wire 7 Small-Cap Stocks to Buy for Large-Scale Gains July 30, 2024 Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. Via InvestorPlace Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs July 23, 2024 What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? Via Investor's Business Daily Topics Government Exposures Political Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day May 13, 2024 The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. Via Investor's Business Daily Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 May 10, 2024 From Edgewise Therapeutics Via Business Wire EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 May 09, 2024 EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 May 09, 2024 Via Benzinga Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors May 07, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) May 06, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies April 23, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) April 15, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session March 28, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 March 27, 2024 From Edgewise Therapeutics Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
